Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
PCVX · Why this verdict
Why Vaxcyte (PCVX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts price in 120% upside to a consensus target of $94.83 on a current price of $49.56, reflecting high expectations for the company's vaccine development pipeline despite current cash losses. Sentiment breakdown | The stock price rises above $75 within 12 months if pipeline milestones are met and analyst coverage expands. | →Stable |
| CounterAnalyst upside targets for cash-burning biotechs are highly volatile and regularly slashed on clinical setbacks; the 9-analyst coverage pool is small, making consensus estimates fragile. | ||
Vaxcyte has negative free cash flow, zero operating margin, and a quality score of 1.2 out of 10, well below the 4.0 floor required to support a buy thesis under the current evaluation framework. Quality breakdown | Quality score rises above 4.0 and free cash flow turns positive within 24 months as pipeline revenue begins materializing. | →Stable |
| CounterEarly-stage biotechs are expected to burn cash; the quality deficit is structural for the development stage and does not necessarily predict long-term failure if clinical outcomes are positive. | ||
The company has missed EPS estimates in all 4 of the last reported quarters with an average negative surprise of -20.2%, reflecting consistently higher-than-expected cash burn rates. Earnings | Quarterly earnings losses narrow to less than 10% below consensus estimates over the next 4 quarters as spending is controlled. | →Stable |
| CounterFor a development-stage biotech, EPS misses primarily reflect R&D investment timing rather than fundamental business deterioration; what matters is pipeline advancement, not quarterly profit. | ||
Vaxcyte depends on Sutro Biopharma and Lonza as critical suppliers, creating two high-concentration dependency risks that could disrupt manufacturing scale-up if either relationship deteriorates. Bear case | The company diversifies its manufacturing partnerships to at least 3 active suppliers within 18 months, reducing single-source dependency. | →Stable |
| CounterSpecialized biotech manufacturing requires deep technical partnerships; forcing diversification too quickly could introduce quality control risks that outweigh concentration concerns. | ||
Analysts price in 120% upside to a consensus target of $94.83 on a current price of $49.56, reflecting high expectations for the company's vaccine development pipeline despite current cash losses.
→StableSentiment breakdown
- Expectation
- The stock price rises above $75 within 12 months if pipeline milestones are met and analyst coverage expands.
CounterAnalyst upside targets for cash-burning biotechs are highly volatile and regularly slashed on clinical setbacks; the 9-analyst coverage pool is small, making consensus estimates fragile.
Vaxcyte has negative free cash flow, zero operating margin, and a quality score of 1.2 out of 10, well below the 4.0 floor required to support a buy thesis under the current evaluation framework.
→StableQuality breakdown
- Expectation
- Quality score rises above 4.0 and free cash flow turns positive within 24 months as pipeline revenue begins materializing.
CounterEarly-stage biotechs are expected to burn cash; the quality deficit is structural for the development stage and does not necessarily predict long-term failure if clinical outcomes are positive.
The company has missed EPS estimates in all 4 of the last reported quarters with an average negative surprise of -20.2%, reflecting consistently higher-than-expected cash burn rates.
→StableEarnings
- Expectation
- Quarterly earnings losses narrow to less than 10% below consensus estimates over the next 4 quarters as spending is controlled.
CounterFor a development-stage biotech, EPS misses primarily reflect R&D investment timing rather than fundamental business deterioration; what matters is pipeline advancement, not quarterly profit.
Vaxcyte depends on Sutro Biopharma and Lonza as critical suppliers, creating two high-concentration dependency risks that could disrupt manufacturing scale-up if either relationship deteriorates.
→StableBear case
- Expectation
- The company diversifies its manufacturing partnerships to at least 3 active suppliers within 18 months, reducing single-source dependency.
CounterSpecialized biotech manufacturing requires deep technical partnerships; forcing diversification too quickly could introduce quality control risks that outweigh concentration concerns.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Vaxcyte is a pre-revenue biotech burning cash with 4 consecutive earnings misses and quality scores well below minimum thresholds, but strong positive price momentum and a 91% analyst upside target reflect speculative optimism around its vaccine pipeline.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.5 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 6.2 |
| MA position | 9.0 |
| Volume | 1.7 |
- ▸Overbought (RSI 79)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.0 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 80%
Insider
4.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 8.2 |
- ▸Modest insider selling — $3,391,760 (0.041% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.8 |
| growth rank | 5.0 |
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.6 |
| support resistance | 0.7 |
| 52w position | 8.7 |
| gap | 5.0 |
Risk (lower is worse)
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.9 |
| days to cover | 0.3 |
| volatility | 1.5 |
| put call | 0.0 |
| implied vol | 0.5 |
| max pain risk | 7.0 |
| beta | 6.1 |
| debt equity | 9.8 |
- ▸Elevated put/call: 3.21
- ▸High IV: 77%
- ▸Concentration risks: 2 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 0B/4M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:6.2>=5.5
- ASYMMETRY:3.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:29d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
3.75
Upside
+56.3%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 9.0 could not lift the engine output above the verdict floor.
The strongest dimensions are Value at 9.0, Sentiment at 7.8, and Momentum at 6.2; the weakest are Quality at 1.6, Catalyst at 2.5, and Risk (lower is worse) at 3.8. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 3.75 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Pipeline Upside Speculation
Trip ifAnalyst consensus price target falls below $60, reducing projected upside to less than 20%.
- P2Cash Burn Quality Deficit
Trip ifCash runway falls below 12 months based on the trailing burn rate exceeding $2.30 per share per quarter.
- P3Earnings Miss Streak
Trip ifAverage quarterly EPS miss exceeds 30% below consensus for 2 consecutive quarters.
- P4Supplier Concentration Risk
Trip ifA key supplier disruption causes manufacturing delay of more than 6 months, as disclosed in an 8-K or press release.